TUMOR CELLS CAN ADOPT THE PHENOTYPE OF STROMAL CELLS BY CELL FUSION

PhD thesis

Zsuzsanna Kurgyis MD

Department of Dermatology and Allergology

University of Szeged

Szeged, Hungary

2017

TUMOR CELLS CAN ADOPT THE PHENOTYPE OF STROMAL CELLS BY CELL FUSION

PhD thesis

Zsuzsanna Kurgyis MD

Supervisor: István Balázs Németh MD PhD

Graduate School of Clinical Medicine

Department of Dermatology and Allergology

University of Szeged

Szeged, Hungary

2017

ARTICLES DIRECTLY RELATED TO THE SUBJECT OF THE THESIS:

I. **Kurgyis Z***, Kemény LV*, Buknicz T, Groma G, Oláh J, Jakab Á, Polyánka H, Zänker K, Dittmar T, Kemény L, Németh IB. *Melanoma-Derived BRAF(V600E) Mutation in Peritumoral Stromal Cells: Implications for in Vivo Cell Fusion.* Int J Mol Sci. 2016 Jun 21;17(6). (*these authors contributed equally) IF: 3.226

II. Kemény LV*, **Kurgyis Z***, Buknicz T, Groma G, Jakab Á, Zänker K, Dittmar T, Kemény L, Németh IB. *Melanoma Cells Can Adopt the Phenotype of Stromal Fibroblasts and Macrophages by Spontaneous Cell Fusion in Vitro.* Int J Mol Sci. 2016 Jun 2;17(6). (*these authors contributed equally) IF: 3.226

INTRODUCTION

Cutaneous melanoma is a highly aggressive malignancy, which often gives rise to metastases and local recurrences following series of tumor-free staging. The histopathological examination of excisional and re-excisional samples together with sentinel lymph node biopsies constitutes a fundamental part of the prognostic evaluation of this disease. Thus, the ability to detect recurrent-tumor-initiating cells in the tissue sample is highly important for prognostic purposes as well as managing this disease.

As a result of tumor heterogeneity, tumor cells often differentially express phenotypic markers, rendering their detection during routine histological assessments difficult. Epithelial-mesenchymal transition, dedifferentiation and acquisition of stem-cell characteristics have been shown to make tumor cells more malignant. Although the mechanisms by which these features are acquired have not yet been fully elucidated, epigenomic and genomic alterations are thought to be the key drivers for malignant heterogeneity.

An increasing body of evidence indicates that cell fusion has not only a physiological role during tissue development and repair, but might also be a hidden force promoting tumor progression. Fibroblasts, mesenchymal stem cells and macrophages have been proposed as fusion partners of tumor cells and several studies have demonstrated that tumor-stromal hybrid cells mostly display more malignant properties than parental tumor cells. Most cell fusion studies are based on experiments on hybrid cells that originate from a single hybrid clone generated with electro- or chemical fusion followed by antibiotic selection. There are only a few studies focusing on spontaneous cell–cell fusion, which is a well-programmed event that requires a specific controlling system. By artificially generating hybrid cells, there is the possibility that unique and important characteristics of hybrid cells might not be discovered. Furthermore, precise analysis of hybrid cell morphology and phenotype might also differ in spontaneous and programmed events.

Numerous studies have suggested that cell fusion may contribute to tumor heterogeneity, moreover, it has been shown that bone marrow derived stem cells can adopt the phenotype of other cells by cell fusion. Therefore, we hypothesized that tumor cells could similarly adopt a stromal phenotype by fusing with peritumoral stromal cells, while maintaining oncogenic properties. Such fusion may lead to a cell type with mixed features that may evade immune recognition and clinical and histopathological detection and, therefore, promote tumor

recurrence. Thus, the detection of these hybrid cells in the intra- and peritumoral stroma could be significant for the accurate histopathological diagnosis, prognosis and subsequent therapy.

AIMS

I. Our aim was therefore to identify potential recurrent tumor-initiating cells in the tumor stroma that display an altered tumor marker expression and therefore stay hidden during histological examinations of tissue samples in melanoma patients.

II. Moreover, we wanted to investigate if spontaneous tumor-stromal cell fusion can lead to the development of such hybrid cells *in vitro*.

MATERIALS & METHODS

Cell Culture

The human melanoma cell lines A375, G361, UACC-257, and SK-MEL-2 were kindly provided by Krisztina Buzás. All cell lines were authenticated using short tandem repeat analysis (Microsynth AG, Balgach, Switzerland) after finishing all experiments. Primary human monocytes were obtained from peripheral blood and isolated using MagCellect Human CD14+ Cell Isolation Kit (R&D Systems, Minneapolis, MN, USA) following gradient centrifugation with Ficoll-Paque (GE Healthcare Life Sciences, Chalfont St Giles, UK). Human dermal fibroblasts were obtained from healthy individuals undergoing plastic surgery with the approval of the local institutional review board and after signing an informed consent. Skin samples were incubated in dispase solution overnight at 4 °C. After the removal of the epidermis, the dermis was incubated in a digestion medium (10.8 mg collagenase, 5 mg hyaluronidase, 0.4 mg deoxyribonuclease, and 0.1 mL fetal bovine serum diluted in 4 mL DMEM low glucose medium) for two hours at 37 °C and filtered through a 100-µm cell strainer. Each melanoma cell line stained with 6 µmol/mL CellTracker Orange (CMTMR) was mixed either with fibroblasts or with freshly isolated monocytes labeled with 10 and 4 µmol/mL CellTracker Green (CMFDA, both from Life Technologies, Carlsbad, CA, USA), respectively, and grown in co-cultures for 24 h. The fibroblast-containing co-cultures were grown in low glucose DMEM supplemented with 5% fetal bovine serum, while the monocyte-containing co-cultures in RPMI 1640 (HEPES modification) with 10% fetal bovine serum and 30 IU/mL GMCSF (R&D Systems). All growth media were supplemented with 1% Penicillin/Streptomycin and 1% Glutamine. All cell culture reagents used are products of

Lonza (Basel, Switzerland), if not specified otherwise. For confocal microscopic visualization 100,000 melanoma cells were seeded either with 200,000 fibroblasts or with 300,000 monocytes on 1-well Lab-Tek® II Chamber Slides™ (Sigma-Aldrich, St. Louis, MI, USA); for flow cytometric analyses, 20,000 melanoma cells either with 40,000 fibroblasts or with 60,000 monocytes were seeded onto 12-well plates (Corning, Corning, NY, USA).

Detection of spontaneous cell fusion

Co-cultures fixed with 4% paraformaldehyde (PFA) were visualized with Fluoview 1000 (Olympus, Tokyo, Japan) confocal laser-scanning microscope with a 40× oil immersion objective. Excitation/emission wavelengths were 405/461, 488/519, and 543/567 nm for DAPI (4′,6-Diamidin-2-phenylindol), CTG, and CTO, respectively. For Z stacking, step size was set to 1 µm. All fluorescent image analyses and three-dimensional reconstructions were performed with ImageJ software (National Insitutes of Health, Bethesda, MD, USA).

Fluorescent *in situ* hybridization (FISH)

Hybrid cells in PFA-fixed co-cultures were identified using AxioImager.Z1 epifluorescent microscope, AxioCamMR3 camera (both from Carl Zeiss Microscopy, Jena, Germany) and 40× oil immersion objective. Excitation/emission filters were set to 353/465, 495/519, and 558/575 nm for DAPI, CTG, and CTO, respectively. After the removal of cover slips, samples were fixed again with 3:1 ratio of methanol and acetate acid followed by photobleaching using Suntest CPS+ Tabletop Xenon Exposure Systems (Thermo Fischer Scientific, Waltham, MA, USA). The monocyte-containing co-cultures were digested using 0.01N HCl, 0.005% pepsin, and fixed with PFA. All samples were incubated in 70% formamide in 2xSSC at 95 °C, then in 70%, 80%, and absolute alcohol each and dried. The X and Yc dual label fluorescent probes (Reagens Ltd., Pécs, Hungary) were put on the samples, denatured at 72 °C, and incubated overnight at 37 °C. Then, samples were washed with 0.3% NP-40 in 2xSSC and incubated in 0.3% NP-40 in 0.4xSSC at 72 °C. FISH signals were visualized with Fluoview 1000 confocal laser-scanning microscope. Excitation/emission wavelengths were 488/519 and 543/567 nm for X and Y chromosomes, respectively.

Fluorescent live cell imaging

Co-cultures grown for 12 h were put into the chamber of a Fluoview 10i-W confocal laser-scanning microscope (Olympus). Excitation/emission wavelengths were 473/519 and 559/567

nm for CTG and CTO, respectively. Five Z-stack images with 3-µm step sizes were taken every 60 min for 12 h at 90 randomly chosen regions using 60× magnification.

Measurement of cell fusion rates

Co-cultures fixed with PFA and stained with DAPI were analyzed in a CyFlow® Space flow cytometer (Sysmex Partec GmbH, Görlitz, Germany). DAPI, CellTracker Green, and CellTracker Orange were detected on channels FL10, FL1, and FL12, respectively.

Assuming that double positive cells in a co-culture result not only from cell fusion, we used transwell cultures for controls, in which monocytes were separated from melanoma cells by a Transwell® (Corning) with a pore size of 3.0 µm; thus, small, stained dead cell particles could cross the membrane but intact cells could not fuse. Therefore, fusion rate was determined as the rate of double positive cells detected in transwell cultures subtracted from that of co-cultures. All data were analyzed using FlowJo software (FlowJo, Ashland, OR, USA).

Immunofluorescent staining

Co-cultures were fixed with PFA. High (for MART1) or low (for CD68) pH target retrieval solution (DAKO, Glostrup, Denmark) was used for heat-induced epitope retrieval. 50% heat-inactivated serum of the monocyte donor was used to block Fc receptors on monocytes and 1% goat serum to prevent the nonspecific binding of the secondary antibody. MART1 (clone 103, 1:200) and CD68 (clone PG-M1, 1:100) mouse monoclonal antibodies (all from DAKO) and their appropriate isotype controls: mouse anti-human IgG1 and IgG3 (both from Biolegend, San Diego, CA, USA) were labeled with goat anti-mouse Alexa 647 antibody (Life Technologies, 1:400). All the reagents were diluted in tris-buffered saline containing 1% bovine serum albumin and, for monocyte-containing co-cultures, 50% heat-inactivated serum of the monocyte donor.

Immunofluorescent stainings were visualized with epifluorescent microscopy. Excitation/emission filters were set to 653/668 nm for Alexa 647.

Tissue Samples and Determination of BRAF Mutational Status

Tissue samples from n = 11 patients with $BRAF^{V600E}$ and n = 5 patients with *$BRAF^{WT}$* melanoma were examined for $BRAF^{V600E}$ protein expression. The corresponding patient

numbers for genetic analyses were n = 11 in the case of *BRAF^V600E* melanoma and n = 8 in the case of *BRAF^WT* melanoma. The *BRAF* mutational status of melanomas was determined with cobas® 4800 BRAF^V600 Mutation Test (Roche Molecular Diagnostics, Pleasanton, CA, USA).

Immunohistochemistry

Formalin-fixed, paraffin-embedded tissue sections of patients with *BRAF^V600E* malignant melanoma were stained with rabbit monoclonal MART1 (clone A19P, DB Biotech, Kosice, Slovakia), mouse monoclonal SMA (clone 1A4, DAKO, Glostrup, Denmark), CD68 (clone PGM1, DAKO), and BRAF^V600E (Clone VE1, Springbio, Pleasanton, CA, USA) primary antibodies. The Bond Polymer Refine Detection Kit and the ChromoPlex 1 Dual Detection Kit (both from Leica, Wetzlar, Germany) were used for the visualization of single and dual histochemical staining, respectively, according to the manufacturer's instructions. All immunohistochemical staining was scanned with a Pannoramic MIDI Slide Scanner (3DHISTECH Ltd., Budapest, Hungary) and analyzed with Pannoramic Viewer software (3DHISTECH Ltd.)

Laser-capture microdissection and detection of the *BRAF^V600E* allele

30-100 cells were dissected from tissue sections stained either with MART1 and SMA or with MART1 and CD68 using a Palm Microbeam (Carl Zeiss Microscopy, Jena, Germany). Samples were digested with proteinase K (QIAGEN, Venlo, The Netherlands). Mutant allele (BRAF_476_mu) and gene reference (Braf_rf) TaqMan® Mutation Detection Assays (Life Technologies, Carlsbad, CA, USA) were used to detect the *BRAF^V600E* mutant allele in the dissected samples. Samples with ΔCt (Ct_{mut}–Ct_{ref}) < 8 and Ct_{mut} < 40 were considered carrying the mutant allele. MART1+ tumor cells dissected from *BRAF^WT* and *BRAF^V600E* melanoma were used as negative and positive controls, respectively.

Statistical analysis

One-way Analysis of Variance and Bonferroni post hoc tests were used to compare the means of fusion rates in different melanoma cell lines. Local recurrence rate in melanoma patients were compared with Fisher's exact test. Level of significance was set to 0.05.

RESULTS

BRAF^V600E protein is expressed in subpopulations of peritumoral stromal cells

To identify potential recurrent tumor-initiating cells, we screened for peritumoral cells that display a stromal phenotype but carry tumor-derived oncogenic information. For this we performed dual immunohistochemical staining on $n = 11$ patient-derived tissue samples of *BRAF^V600E* melanoma with MART1 (melanoma antigen recognized by T-cells) and BRAF^V600E. *BRAF^V600E* is an oncogenic somatic mutation present in approximately 50%–60% of malignant melanomas. The staining revealed that, in addition to melanoma cells, BRAF^V600E is also expressed in some subpopulations of MART1− peritumoral stromal cells with fibroblast and macrophage morphology.

To investigate whether the mutant protein originated from the tumor cells, we tested the stroma of $n = 5$ *BRAF^WT* melanomas for the presence of the BRAF^V600E protein. However, we could not detect the mutant protein in *BRAF^WT* melanoma tissue samples, suggesting that the presence of the mutation in the stromal cells could not occur without the neighboring melanoma cells carrying the mutation. Nevertheless, though the antibody has been reported to be highly specific, and we did not see any specific signals in *BRAF^WT* melanoma tissue samples, we cannot rule out nonspecific staining especially in case of macrophages.

Some peritumoral fibroblasts and macrophages carry the BRAF^V600E mutation in primary melanoma, melanoma metastasis and a tumor-free re-excision sample

We wanted to confirm that the staining we observed in the *BRAF^V600E* samples was specific, so we examined whether this oncogenic information is also present in the peritumoral cells at the genetic level. Therefore, we dual-stained *BRAF^V600E* primary melanoma tissue samples with MART1 and either the fibroblast marker smooth muscle actin (SMA) or the monocyte-macrophage marker CD68, and isolated cell compartments consisting of 20–50, clearly MART1− but either SMA+ or CD68+ cells with fibroblast and macrophage morphology, respectively, using laser-capture microdissection. Subsequent allele specific mutation detection PCR analyses performed on the dissected stromal cells revealed that the *BRAF^V600E* mutant allele was present in peritumoral MART1−/SMA+ fibroblasts and MART1−/CD68+ macrophages. In addition to primary melanoma tissue samples, such peritumoral stromal cells carrying the melanoma-derived mutation were detected in lymph node and cutaneous melanoma metastases. Surprisingly, *BRAF^V600E* was also detected when analyzing MART1−

macrophages dissected from a histologically tumor-free re-excision sample from a patient who subsequently developed a local recurrence.

Having dissected peritumoral stromal cells from $BRAF^{WT}$ melanoma tissue samples, we only detected the wild-type allele, providing further evidence that $BRAF^{V600E}$ is only present in peritumoral cells that are adjacent to a mutant tumor. In total, we examined 86 dissected samples of 19 patients, and out of 12 patients with $BRAF^{V600E}$ melanoma, we found $BRAF^{V600E}$-containing peritumoral cells in the tissue samples of five patients. The proportion of mutant alleles detected in these cell populations varied between 0.5% and 30%.

These results indicate that some peritumoral stromal cells contain a melanoma-derived oncogene at both the DNA and protein levels. The possible recurrent tumor-initiating potential of these cells is supported by our clinical observations of the local recurrence rate in our melanoma patients diagnosed before 1998. Patients who had primary melanoma removed completely, based on a clinical diagnosis of a non-melanoma skin lesion and with histologically tumor-free excision margins developed local recurrence significantly more often ($p = 0.7 \times 10^{-5}$, 12 out of 228 patients) than patients with melanomas excised with 5-cm margins (8 out of 935 patients), implying that recurrent-tumor-initiating cells could indeed be present in the peritumoral stroma of malignant melanoma.

Melanoma cells spontaneously fuse with fibroblasts and monocytes *in vitro*

In order to investigate how cells displaying a stromal phenotype and containing melanoma-derived genetic information could form, we co-cultured various human melanoma cell lines either with primary human dermal fibroblasts or with freshly isolated human monocytes for 24 hours. CellTracker Orange (CTO) and CellTracker Green (CTG) fluorescent vital dyes were used to identify melanoma cells and fibroblasts or monocytes, respectively.

After 24 hours, we observed the spontaneous formation of hybrid cells containing both CTO and CTG with laser scanning confocal microscopy. The subsequent three-dimensional reconstruction of such double positive cells demonstrated that the double fluorescence was detected in a single cell and did not derive from two overlapping cells. To further confirm the fusion of melanoma cells and stromal cells at the genetic level, we used parental cells from donors of different genders and performed fluorescent *in situ* hybridization targeting the X and Y chromosomes in the hybrid cells to visualize and distinguish genetic material from both parental cells. For these experiments, A375 female melanoma cells were co-cultured with

fibroblasts or monocytes from a male donor. Hybrid cells from each co-culture containing the sex chromosomes from both parental cells have been detected.

To examine the possibility that the double positivity results from macrophages phagocytosing cell debris of dead melanoma cells, we used transwells in a set of co-culture experiments. The transwells separated the monocytes plated onto 12-well plates from the melanoma cells plated on the transwells and thereby inhibited cell fusion, which requires cell-cell contact but allowed phagocytosis of cell debris by monocytes. After 24 hours harvested cells were mixed and the rate of double positive cells in co-cultures with and without transwells was measured using flow cytometry. Since we observed some double positive events in the transwell cultures, we estimated the rate of hybrid cells by subtracting the rate of double positive cells detected in transwell cultures from that of co-cultures without transwells. In this way the proportion of hybrid cells in the different melanoma cell line – monocyte co-cultures varied between 0.5–4.39%.

Hybrid cells are indistinguishable from stromal cells based on cell morphology and phenotype

Next, we examined the appearance of the hybrid cells and found that in all melanoma cell lines used for co-cultures, most of the hybrid cells were indistinguishable from fibroblasts or monocytes based merely on cell size and morphology.

Moreover, all hybrid cells contained one or two nuclei, but no multinucleated cells were detected. Since hybrid cells could adopt the morphology of stromal cells and, more importantly, lose the characteristic morphology of melanoma cells, we examined commonly used phenotypic markers to better characterize the CTG +/CTO + hybrid cells and to investigate whether these markers enable their discrimination from conventional stromal cells. Interestingly, some melanoma-monocyte hybrids were positive for CD68. However, when the MART1-expressing G361 melanoma cell line was used, we detected hybrid cells that lost the expression of MART1 both in monocyte and in fibroblast co-cultures. These results provide evidence that spontaneously formed melanoma-stromal cell hybrids can adopt the morphology and phenotype of stromal cells while losing tumor-cell characteristics.

DISCUSSION

After the complete resection of primary cutaneous melanoma, patients occasionally develop local recurrence which is considered as an independent prognostic factor. This can be explained by hidden tumor-initiating cells containing tumor-derived information as local minimal residual disease in the peritumoral area. In addition, such tumor-derived cells can also spread to distant areas such as lymph nodes and parenchymal organs.

Tumor cells are commonly identified during routine histological assessments using markers that are often insufficiently sensitive to distinguish tumor cells from stromal cells, which is supported by additional genetic analyses of sentinel lymph nodes. The incomplete removal of tumor cells often results in a higher recurrence rate: narrow excision margins lead to a more frequent tumor recurrence, even if the excision margins are assessed to be tumor-free. These data imply that recurrent-tumor-initiating cells with an altered phenotype could indeed be present in the peritumoral stroma of malignant melanoma, allowing them to remain undetected during routine diagnostic procedures.

We examined patient-derived melanoma tissue samples and detected peritumoral cells displaying stromal cell phenotype but carrying the oncogenic $BRAF^{V600E}$ mutation characteristic of the adjacent melanoma cells. First, we detected the mutated protein with a mutation-specific antibody. Even though nonspecific staining of the antibody in peritumoral mononuclear cells have been reported, the fact that peritumoral fibroblasts were also positive argues for a specific signal. Moreover, we only observed positivity in peritumoral cells adjacent to $BRAF^{V600E}$ melanoma but not in wild type. Nevertheless, to confirm the presence of the oncogene in these cells, we also performed genomic analyses and showed that the mutation is also present in cells with a stromal cell phenotype adjacent to $BRAF^{V600E}$ melanoma cells at the genetic level. We believe the mutation originates from tumor cells, as we did not detect the mutation in the stroma of $BRAF^{WT}$ melanoma samples. Possible mechanisms for the transfer of tumor-derived information to stromal cells include tumor-stromal cell fusion, exosomal protein transfer and the phagocytosis of tumor debris. The obtained *ex vivo* results i.e. subpopulations of peritumoral stromal cells carrying the $BRAF^{V600E}$ mutation not only at protein but also at genomic level suggest that melanoma-stromal cell fusion may be one of the underlying mechanisms. It is important to mention that, since melanoma cells can lose MART1 expression, especially on the periphery of the tumor,

cell morphology and the expression patterns of CD68 and SMA were all taken into account during the process of peritumoral cell identification.

We show that human melanoma cells fuse with primary human fibroblasts and human peripheral blood-derived monocytes *in vitro*. By combining cytosolic intravital dyes and *in situ* hybridization techniques, we could identify the spontaneously formed hybrid cells between melanoma cells and primary stromal cells. This allows the studying of individual spontaneously formed hybrid cells, which is especially interesting, as there are currently no unique sets of markers to identify fused cells *in vivo*. There are only few reports on identifying fused cells in patients' biopsies. These studies pre-select potential hybrid tumor cells using immunohistological approaches and confirm cell fusion events using genetic analyses. Therefore, further *in vitro* work is needed to further characterize and identify markers unique to hybrid cells that would allow their identification *in vivo* as well.

We demonstrate that the fusion takes place spontaneously with fusion rates of more than 0.1%, which are surprisingly high compared to fusion rates reported in previous studies using electro- or chemical fusion followed by antibiotic selection. One possible explanation for the high fusion rates observed with flow cytometry is that most of the hybrid cells die shortly after formation, partly due to mitotic stress, and they may be very sensitive to any additional stress such as antibiotics or sorting. It should be noted that fusion rates in our hands varied significantly among different cell donors and even cell densities. Supposing that hybrid cells are formed constantly at a similar rate *in vivo* in an inflamed tumor microenvironment, even if the majority of the hybrid cells cannot survive, this rate should be sufficient for the detection of hybrid clones *in vivo*.

Several studies in mice imply that cell fusion may also take place in human tumors *in vivo*. However, it is very difficult to detect tumor–stromal cell fusion on a genetic level in humans. To address this difficulty, tumors developing in patients who had received bone marrow transplants have been investigated: genetic material originating from the donor was detected in the patients' tumor cells, strongly suggesting a fusion event between recipient tumor cells and donor hematopoietic cells. However, inflammation resulting from treatment (e.g., whole body irradiation or chemotherapeutics) preceding bone-marrow transplantation has been reported to promote cell fusion; therefore, further studies investigating fusion between tumor and stromal cells are clearly required.

Cell fusion studies based on *in vitro* observations and mouse models suggest that cell fusion might contribute to tumor progression by increasing the tumor's metastatic potential and by inducing drug resistance to certain tumor–stromal cell hybrid clones. In addition, tumor cells can acquire stem-cell-like properties by fusing with stromal cells. Therefore, cell fusion might serve as an evolutionary mechanism for tumor cells to acquiring properties that allow them to react quickly to a changing environment, such as during chemotherapy or irradiation, or even to evade immune recognition. The malignant behavior of these tumor–stromal hybrid cells in mice is supported by the finding that, even though fusion hybrids of tumor cells and multipotent stromal cells first show a predominantly mesenchymal morphology, they subsequently undergo a reversal to a cancer-like phenotype and that these hybrid cells form invasive and metastatic tumors in mice. However, the majority of *in vitro* spontaneously formed hybrid cells undergo apoptosis, most likely as a result of mitotic stress. Therefore, it is also possible that tumor-stromal cell fusion is rather an antitumor mechanism, eliminating most of the hybrid tumor cells but occasionally giving rise to highly malignant tumor cell clones. Furthermore, as our results suggest, cell fusion might provide an alternative mechanism for phenotype switching; thus, melanoma cells could become undetectable with standard histopathological methods that rely on the thorough examination of cell morphology and the expression of melanocytic markers.

In conclusion, our results suggest that peritumoral stromal cells contain melanoma-specific oncogenic properties such as the *BRAF^{V600E}* mutation derived from the neighboring tumor cells, potentially as a result of cell fusion. In addition, we have here provided evidence that melanoma cells can adopt the phenotype of stromal fibroblasts and macrophages by spontaneous cell fusion *in vitro*. Although further studies are needed to functionally characterize these hybrid cells, based on literature data these cells can, following a reversal to a tumorous phenotype, possibly contribute to tumor recurrence. These cells are phenotypically indistinguishable from peritumoral stromal cells and are therefore not accurately detectable by routine histological assessments. Our results highlight the importance of genetic analysis and mutation-specific antibodies, especially in the case of histologically tumor-free tissue samples, for which improved methods for the detection of tumor cells have already been shown to better predict survival and outcome. Although yet to be confirmed in clinical trials, the use of genetic analyses and mutation-specific antibodies could have important prognostic and therapeutic consequences and could enable the detection of recurrent-tumor-initiating cells.

SUMMARY

Melanoma often recurs in patients after the removal of the primary tumor, suggesting the presence of tumor-initiating cells that are undetectable using standard diagnostic methods. As cell fusion has been implicated to facilitate the alteration of a cell's phenotype, we hypothesized that cells in the peritumoral stroma having a stromal phenotype that initiate recurrent tumors might originate from the fusion of melanoma and stromal cells.

Here, we showed that in patients with $BRAF^{V600E}$ melanoma, MART1-negative peritumoral stromal cells express BRAF^{V600E} protein. To confirm the presence of the oncogene at the genetic level, peritumoral stromal cells were microdissected and screened for the presence of $BRAF^{V600E}$ with a mutation-specific polymerase chain reaction. Interestingly, cells carrying the $BRAF^{V600E}$ mutation were not only found among cells surrounding the primary tumor but were also present in the stroma of melanoma metastases as well as in a histologically tumor-free re-excision sample from a patient who subsequently developed a local recurrence. We did not detect any $BRAF^{V600E}$ mutation or protein in the peritumoral stroma of $BRAF^{WT}$ melanoma. To investigate how such cells can form, we co-cultured melanoma cells with fibroblasts or monocytes. We showed that melanoma cells spontaneously fuse with human dermal fibroblasts and human peripheral blood monocytes *in vitro*. The hybrid cells' nuclei contained chromosomes from both parental cells and were indistinguishable from the parental fibroblasts or macrophages based on their morphology. Our results suggest that, by spontaneous cell fusion *in vitro*, tumor cells can adopt the morphology of stromal cells while still carrying oncogenic, tumor-derived genetic information.

In conclusion, these data suggest that some peritumoral stromal cells contain melanoma-derived oncogenic information, potentially as a result of cell fusion. These hybrid cells display the phenotype of stromal cells and are therefore undetectable using routine histological assessments. Thus, our results highlight the importance of genetic analyses and the application of mutation-specific antibodies in the identification of potentially recurrent tumor-initiating cells, which may help better predict patient survival and disease outcome.

ACKNOWLEDGEMENTS